Brief: Oncolytics Biotech® Partner Adlai Nortye Advances To The Second Dose Escalation Cohort Of The Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment In Breast Cancer
27/01/2022 13:54
Jan 27 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® PARTNER ADLAI NORTYE ADVANCES TO THE
SECOND
DOSE ESCALATION COHORT OF THE CHINESE BRIDGING TRIAL EVALUATING
PELAREOREP-PACLITAXEL COMBINATION TREATMENT IN BREAST CANCER
* ONCOLYTICS BIOTECH INC - ENROLLMENT IN FIRST DOSE
ESCALATION IS
COMPLETE WITH NO SAFETY ISSUES REPORTED TO DATE
Source text for Eikon: ID:nCNWG3bYla
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer